Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)
Florida Institute for Human and Machine Cognition · with University of Florida, Oklahoma Medical Research Foundation · NCT06507189
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 60+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 250
- US sites recruiting
- 2
- Study start
- January 27, 2025
- Record last updated
- August 10, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments that compromise healthspan and quality of life. Exercise is a multipotent treatment with promise to mitigate most aging hallmarks, but there is substantial variability in exercisƒe responsiveness. Combining endurance and resistance training in alignment with public health guidelines will be used to better understand variable exercise responsiveness in older adults with the ultimate goal of improving each older adult's capacity to attain the many health benefits of exercise.
Being studied: Combined endurance and resistance training
Conditions: Aging; Aging Well
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male or female aged 60 or above
- Free of chronic disease
- No structured exercise program (2 or more bouts/wk) within previous 12 months
- Cognitively capable of providing informed consent
Exclusion Criteria
- Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and/or testing bouts
- Cardiopulmonary disorders or reduced breathing capacity
- Metabolic diseases including markers of liver disease (ALT > 52 U/l) and type 2 diabetes (HbA1C = or > 6.5, fasting blood glucose = or > 126 mg/dl)
- Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, dementia, current cancer diagnosis or within 2 yr remission, cerebrovascular disease)
- Any current infectious disease
- Life expectancy \< 1 year
- Insulin sensitizing/blood glucose lowering agents such as metformin or metabolic weight loss agents (e.g. GLP-1 agonists)
- High dose statin (dose equivalent of 40 mg/d or higher simvastatin)
- Lidocaine allergy
- Regular tobacco use and/or vaping
- Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
- BMI 35.0 kg/m2 or higher
- Unable to commit to \~6 months required to complete the study
Recruiting US locations
Florida Institute for Human and Machine Cognition
Pensacola, FL 32502
Site contact: Craig Tuggle · 205-352-6036 · ctuggle@ihmc.org
Oklahoma Medical Research Foundation
Oklahoma City, OK 73104
Site contact: Ben Miller, PHD · 405-271-7767 · Benjamin-Miller@omrf.org
Study contacts (from the official record)
- Craig Tuggle · 205-352-6036 · ctuggle@ihmc.org
- Marcas Bamman, PHD · mbamman@ihmc.org
Similar studies in Florida
All healthy volunteers studies in Florida →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4302814 in Healthy Participants
Eli Lilly and Company
- Location
- Daytona Beach, FL
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Orlando, FL + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol
BioCorRx Pharmaceuticals Inc
- Location
- Miami, FL
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Miami, FL + 6 other US sites
- Eligibility basics
- Ages 18–65